George Philip

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint Single-dose montelukast or salmeterol as protection against exercise-induced bronchoconstriction
    George Philip
    Merck Research Laboratories, Respiratory and Allergy Department, Mail code RY34B 348, 126 East Lincoln Ave, Rahway, NJ 07065, USA
    Chest 132:875-83. 2007
  2. ncbi request reprint Efficacy of montelukast for treating perennial allergic rhinitis
    George Philip
    Merck Research Laboratories, Respiratory and Allergy Department, Rahway, NJ 07065, USA
    Allergy Asthma Proc 28:296-304. 2007
  3. doi request reprint Reports of suicidality in clinical trials of montelukast
    George Philip
    Merck and Co, Inc, North Wales, PA 19454, USA
    J Allergy Clin Immunol 124:691-6.e6. 2009
  4. doi request reprint Analysis of behavior-related adverse experiences in clinical trials of montelukast
    George Philip
    Merck and Co, Inc, North Wales, PA 19454, USA
    J Allergy Clin Immunol 124:699-706.e8. 2009
  5. doi request reprint Baseline predictors of placebo response in exercise-induced bronchoconstriction (EIB): pooled regression analysis >from three studies of montelukast in EIB
    George Philip
    Merck Research Laboratories, North Wales, Pennsylvania 19454, USA
    J Asthma 47:935-41. 2010
  6. doi request reprint A phase I randomized, placebo-controlled, dose-exploration study of single-dose inhaled montelukast in patients with chronic asthma
    George Philip
    Merck Research Laboratories, North Wales, PA 19454, USA
    J Asthma 47:1078-84. 2010
  7. doi request reprint The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma
    George Philip
    Clinical Research, Merck and Co, Inc, Whitehouse Station, NJ 19454, USA
    J Asthma 48:495-502. 2011
  8. ncbi request reprint Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast
    George Philip
    Merck Research Laboratories Rahway, NJ 07065, USA
    J Asthma 44:213-7. 2007
  9. doi request reprint Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis
    George Philip
    Merck Research Laboratories, Rahway, NJ, USA
    J Allergy Clin Immunol 124:942-8.e1-9. 2009
  10. ncbi request reprint The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis
    George Philip
    Merck Research Laboratories, Rahway, NJ, USA
    Curr Med Res Opin 20:1549-58. 2004

Collaborators

Detail Information

Publications20

  1. ncbi request reprint Single-dose montelukast or salmeterol as protection against exercise-induced bronchoconstriction
    George Philip
    Merck Research Laboratories, Respiratory and Allergy Department, Mail code RY34B 348, 126 East Lincoln Ave, Rahway, NJ 07065, USA
    Chest 132:875-83. 2007
    ..The present objective was to assess the onset and duration of this protective action in a trial that included both positive and negative controls...
  2. ncbi request reprint Efficacy of montelukast for treating perennial allergic rhinitis
    George Philip
    Merck Research Laboratories, Respiratory and Allergy Department, Rahway, NJ 07065, USA
    Allergy Asthma Proc 28:296-304. 2007
    ..In a pooled post hoc analysis, montelukast provided consistent improvement in daytime nasal symptoms over 6 weeks, supportive of an overall benefit in PAR...
  3. doi request reprint Reports of suicidality in clinical trials of montelukast
    George Philip
    Merck and Co, Inc, North Wales, PA 19454, USA
    J Allergy Clin Immunol 124:691-6.e6. 2009
    ..In recent years, a number of drugs and drug classes have come under scrutiny by the US Food and Drug Administration regarding suicidality (including suicidal behavior and ideation)...
  4. doi request reprint Analysis of behavior-related adverse experiences in clinical trials of montelukast
    George Philip
    Merck and Co, Inc, North Wales, PA 19454, USA
    J Allergy Clin Immunol 124:699-706.e8. 2009
    ..Frequencies of behavior-related adverse experiences (BRAEs) in controlled clinical studies of leukotriene modifier drugs have not been summarized...
  5. doi request reprint Baseline predictors of placebo response in exercise-induced bronchoconstriction (EIB): pooled regression analysis >from three studies of montelukast in EIB
    George Philip
    Merck Research Laboratories, North Wales, Pennsylvania 19454, USA
    J Asthma 47:935-41. 2010
    ..Evaluating patterns of placebo response and patient-related factors driving placebo response could facilitate more efficient clinical trials for EIB...
  6. doi request reprint A phase I randomized, placebo-controlled, dose-exploration study of single-dose inhaled montelukast in patients with chronic asthma
    George Philip
    Merck Research Laboratories, North Wales, PA 19454, USA
    J Asthma 47:1078-84. 2010
    ..The efficacy of oral montelukast has been well established in asthma and allergic rhinitis in adults and children. The purpose of this study was to evaluate dose-related bronchodilation and tolerability of inhaled montelukast...
  7. doi request reprint The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma
    George Philip
    Clinical Research, Merck and Co, Inc, Whitehouse Station, NJ 19454, USA
    J Asthma 48:495-502. 2011
    ..The purpose of this study was to evaluate the efficacy of inhaled montelukast added to inhaled mometasone...
  8. ncbi request reprint Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast
    George Philip
    Merck Research Laboratories Rahway, NJ 07065, USA
    J Asthma 44:213-7. 2007
    ..At this timepoint, more patients taking montelukast (45/54) than taking placebo (37/54) were protected against EIB (p = 0.039). We concluded that montelukast provided significant protection against EIB at 2 hours after a single dose...
  9. doi request reprint Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis
    George Philip
    Merck Research Laboratories, Rahway, NJ, USA
    J Allergy Clin Immunol 124:942-8.e1-9. 2009
    ..Allelic variants in the prostaglandin D(2) receptor type 1 (DP1) gene (PTGDR) have been suggested to be associated with asthma susceptibility...
  10. ncbi request reprint The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis
    George Philip
    Merck Research Laboratories, Rahway, NJ, USA
    Curr Med Res Opin 20:1549-58. 2004
    ..The objective of this study was to evaluate montelukast 10 mg daily as treatment for allergic rhinitis in patients with symptomatic allergic rhinitis and active asthma during the allergy season...
  11. doi request reprint Onset and duration of attenuation of exercise-induced bronchoconstriction in children by single-dose of montelukast
    Yasmine S Wasfi
    Merck and Co, Inc, Whitehouse Station, New Jersey, USA
    Allergy Asthma Proc 32:453-9. 2011
    ..034), and AUC at 2 hours (p = 0.022) and 24 hours (p = 0.013). Single-dose montelukast provided rapid and sustained EIB attenuation in children. Clinicaltrials.gov identifier: NCT00534976...
  12. ncbi request reprint Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis
    Janet van Adelsberg
    Merck and Co Inc Rahway, New Jersey, USA
    Ann Allergy Asthma Immunol 90:214-22. 2003
    ..Symptoms of allergic rhinitis are mediated in part by cysteinyl leukotrienes...
  13. ncbi request reprint Validation of the nighttime symptoms score as a clinically relevant measure of allergic rhinitis
    Nancy C Santanello
    Merck Research Laboratories, Rahway, New Jersey, USA
    Allergy Asthma Proc 27:231-9. 2006
    ..Sleep quality questions measure aspects of SAR that are not captured by daytime SAR symptoms. The results show that the NSS is a valid and relevant clinical measure of the impact of nighttime sleep disturbance on AR patients...
  14. ncbi request reprint Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast
    David S Pearlman
    Colorado Allergy and Asthma Centers, PC, Denver, Colorado 80230, USA
    Ann Allergy Asthma Immunol 97:98-104. 2006
    ..Leukotriene modifiers have been shown to protect against exercise-induced bronchoconstriction (EIB) with repeated, chronic dosing...
  15. ncbi request reprint Montelukast effectively treats the nighttime impact of seasonal allergic rhinitis
    Eli O Meltzer
    Allergy and Asthma Medical Group and Research Center, San Diego, CA 92109, USA
    Am J Rhinol 19:591-8. 2005
    ..Nighttime problems constitute a significant burden on the quality of life of patients with seasonal allergic rhinitis (SAR). The aim of this study was to evaluate the effectiveness of montelukast on nighttime AR symptoms...
  16. ncbi request reprint Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis
    Piyush Patel
    Allied Research International, Mississauga, Ontario, Canada
    Ann Allergy Asthma Immunol 95:551-7. 2005
    ..Perennial allergic rhinitis (PAR) is a persistent allergic inflammation of the upper respiratory tract due to year-round allergen exposure...
  17. ncbi request reprint Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure
    Tamara T Perry
    Division of Allergy and Immunology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Ann Allergy Asthma Immunol 93:431-8. 2004
    ..Challenge with short-term exposure to airborne cat allergen in sensitized patients produces pulmonary function changes and rhinitis symptoms...
  18. ncbi request reprint Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies
    Paul Chervinsky
    New England Research Center, North Dartmouth, Massachusetts, USA
    Ann Allergy Asthma Immunol 92:367-73. 2004
    ..Montelukast, a potent leukotriene receptor antagonist, is an effective therapy for symptoms of seasonal allergic rhinitis, a disease governed by patients' individual sensitivity and exposure to relevant allergens...
  19. ncbi request reprint Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall
    Anjuli S Nayak
    University of Illinois, College of Medicine at Peoria, USA
    Ann Allergy Asthma Immunol 88:592-600. 2002
    ..Histamine and cysteinyl leukotrienes seem to be important mediators of allergic rhinitis...
  20. ncbi request reprint Onset of efficacy of montelukast in seasonal allergic rhinitis
    Steven F Weinstein
    Allergy and Asthma Specialists Medical Group and Research Center, Huntington Beach, California 92647, USA
    Allergy Asthma Proc 26:41-6. 2005
    ..001) in the daytime eye symptoms score was seen by day 1 (-0.08 [-0.12, -0.03]), after the first dose. In patients treated for SAR, montelukast has a beneficial effect on daytime and nighttime symptoms by the 2nd day of daily therapy...